Astellas Pharma : Presentation Material for R&D Meeting

INITIATIVES FOR GENE THERAPY

R&D Meeting - March 9, 2022

Astellas Proprietary Information

CAUTIONARY STATEMENT	2
REGARDING FORWARD-LOOKING INFORMATION

In this material, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas Pharma. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively,

1. the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties.

Information about pharmaceutical products (including products currently in development) which is included in this material is not intended to constitute an advertisement or medical advice.

Astellas Proprietary Information

AGENDA	3

Introduction

1. Kenji Yasukawa, Ph.D.
   President and Chief Executive Officer

Building Leadership in Gene Therapy

1. Mathew Pletcher, Ph.D.
   Division Head of Gene Therapy Research & Technical Operations

Update on Clinical Programs in Gene Therapy

1. Bernhardt (Bernie) Zeiher, M.D. Chief Medical Officer

Astellas Proprietary Information

INTRODUCTION

Kenji Yasukawa, Ph.D.

President and Chief Executive Officer

Astellas Proprietary Information

WHY WE WORK ON GENE THERAPY	5

Gene therapy has the potential to be transformative for patients, their families and society

by addressing the root cause of disease, which provides a variety of VALUEs

FOCUS AREA APPROACH

Biology	Modality/
Technology
Pathophysiology	Versatile
characterized	technology

Disease

Disease with

high unmet medical needs

Primary Focus Genetic Regulation has been selected based on;

• Scientific validity
• Feasibility
• Identified lead program and potential follow-on programs

ASTELLAS' COMMITMENT TO GENE THERAPY

	2010's	2020	2021	2022
	Exploratory research	Acquisition of	Astellas Gene Therapies	New manufacturing
	on gene therapy	Audentes	as Gene Therapy	facility in Sanford,
			Center of Excellence	North Carolina1
1. Scheduled to be operational and GMP-ready by mid-2022

Astellas Proprietary Information